Celera Genomics announced a major restructuring that will eliminate 132 jobs and purge the company’s genome sequencing and online information business. Sixteen percent of the workforce will be let go, mostly in DNA sequencing, data management and analysis support, sales, and general administration.
Find “Celera Axes 132 Jobs to Refocus On Drug Development” by searching: jobs
Raking in the Bucks
Venture-capital investment in biotech companies in the second quarter grew 44 percent over the same period last year even as overall VC spending was cut in half, according to an audit by a private-equity tracking firm.
Find “Though Overall VC Spending Stumbles and Falls, Private Equity Shines on Biotech” by searching: VC
Fake That, Criminals
A Taiwanese company is using DNA technology as a new weapon against counterfeit consumer products. To check for piracy, labels loaded with several-kb-length DNA segments can be tested on the spot with reagents or sent back to the company for sequencing.
Find “Using DNA to Foil Counterfeiting: Genes On Your Jeans?” by searching: jeans
Like Father, Like Son
As two of the founding fathers (or perhaps father and son) of proteomics, Norman and Leigh Anderson have worked steadily over the past 25 years to expand the reach of proteomics technology. Their departure from Large Scale Biology Corporation marks a new chapter in their work: Norman Anderson said they have been working on how to apply the technology they’ve developed to identifying potentially virulent proteins.
Find “Andersons Mull Using Proteomics for Defense; LSBC Stays the Course” by searching: LSBC
What if researchers had to reinterpret all their human gene expression data, or if microarrays needed to be redesigned altogether? These scenarios are possible, according to a new paper, estimating that about half of all human genes make several transcripts that vary significantly in length.
Find “Human Microarrays Might Need Makeover, Recent Study Suggests” by searching: makeover
Join the Club
According to I3C officials, the organization behind the technology is wholly different than it was a year ago. Hewlett-Packard recently agreed to join and a number of other organizations, including Biogen, Agilent, and the University of Manchester, are at varying stages of signing on the dotted line.
Find “I3C Grows Up: Two Specs on the Table, HP on Board, Others Pledged to Follow” by searching: I3C